Activation of Factor X by Factor VIIa Complexed with Human-mouse Tissue Factor Chimeras Requires Human Exon 3

Carrie H Fang; T-C Lin; Arabinda Guha; Yale Nemerson; William H Konigsberg

doi:10.1055/s-0038-1650584

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1996; 76(03): 361-368
DOI: 10.1055/s-0038-1650584

Original Article

Schattauer GmbH Stuttgart

Activation of Factor X by Factor VIIa Complexed with Human-mouse Tissue Factor Chimeras Requires Human Exon 3

Carrie H Fang

¹The Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT

,

T-C Lin

¹The Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT

,

Arabinda Guha

²Th Departments of Medicine and Biochemistry, Mount Sinai School of Medicine, City University of New York, New York, NY, USA

,

Yale Nemerson

²Th Departments of Medicine and Biochemistry, Mount Sinai School of Medicine, City University of New York, New York, NY, USA

,

William H Konigsberg

¹The Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT

› Author Affiliations

Abstract

PDF Download

Summary

In an attempt to define sequence elements in human and mouse tissue factor (TF) that are responsible for the species specificity observed in their interaction with human factor VII_a (HVII_a), we constructed human-mouse chimeric TF cDNAs, inserted them into plasmid vectors, and induced their expression in E.coli. Assays for procoagulant activity were carried out with the resulting E. coli lysates using (HVII_a) human and mouse (MVII_a). The ratio of the procoagulant activities, HVII_a/MVII_a, revealed that human TF exon 3 was essential for activity when the TF:VII_a complex was formed with HVII_a. By ligating the maltose binding protein (MBP) gene to TF cDNAs it was possible to construct, express and purify MBP-TF chimeras as well as to estimate their specific activities. With selected MBP-TF chimeras and HVIIa we determined kinetic parameters for the activation of human factor X. Replacement of exon 3 in human TF cDNA with the corresponding exon from mouse TF cDNA resulted in both lower affinity for HVII_a and failure to convert bound HVII_a into a potent protease

PDF (469 kb)

References

References
1 Nemerson Y. The reaction between bovine tissue factor and factors VII and X. Biochemistry 1966; 5: 601-608
2 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
3 Edgington TS, Mackman N, Brand K, Ruf W. The structural of expression and function of tissue factor. Thromb Haemost 1991; 66: 64-79
4 Carson D, Brozna JP. Role of tissue factor in the production of thrombin. Blood Coag. Fibrinol 1993; 4: 281-292
5 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
6 Bach R. Initiation of coagulation by tissue factor. CRC Critical Reviews in Biochemistry 1988; 23: 339-368
7 Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagualtion: Evidence for a conformational cage. Biochemistry 1986; 25: 4020-4033
8 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathology 1989; 134: 1087-1097
9 Cole EH, Schulman J, Urowitz M, Keystone E, Williams C, Levy GA. Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus. J Clin Invest 1985; 75: 861-868
10 Halloran P, Aprile M, Haddad G, Roginette M. The significance ofelevated procoagulant activity in the monocytes of renal transplant recipients. Transplant Proc 1982; 14: 669-672
11 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavorable prognosis. Thromb Haemost 1983; 49: 5-7
12 Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the artherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2834
13 Silverberg S, Nemerson Y, Zur M. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. J Biol Chem 1977; 252: 8481-8488
14 Kadish JL, Wenc KM, Dvorak HF. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. JNCI 1983; 70: 551-557
15 Janson TL, Stormoken H, Prydz H. Species Specificity of tissue thromboplastin. Hemostasis 1984; 14: 440-444
16 Muller YA, Ultsch MH, Kelley RF, Abraham M. de Vos. Structure of the extracellular domain of human tissue factor: location of the factor Vila binding site. Biochemistry 1994; 33: 10864-10870
17 Harlos K, Martin DMA, O’Brien DP, Jones EY, Stuart DI, Pollkarpov I, Miller A, Tuddenham EGD, Boys CWG. Crystal structure of the extracellular region of human tissue factor. Nature 1994; 370: 662-666
18 Banner DW, D’Acry A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation of factor Vila with soluble tissue factor. Nature 1996; 380: 41-46
19 Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 1985; 82: 488-492
20 Hartzell S, Ruder K, Langan A, Lau LF, Nathans D. A growth factor responsive gene of murine BALB/c 3T3 cells encodes a protein homologous to human tissue factor. Mol Cell Biol 1989; 9: 2567-2573
21 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467
22 Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct sensitive high-level expression of cloned genes. Mol Biol 1986; 189: 113-130
23 Studier W, Rosenberg AH, Dunn JJ, Dubendorff JW. Use of the T7 RNA polymerase to direct expression of cloned genes. Meth Enzymol 1990; 185: 66-89
24 Maina CV, Riggs PD, Grandea AG III, Slatko BE, Moran LS, Taglamonte JA, McReynolds LA, Guan CD. An Escherichia coli vector to express and purify foreign proteins by fusion and separation from maltose-binding protein. Gene 1988; 74: 365-373
25 Guha A, Bach R, Konigsberg W, Nemerson Y. Affinity purification of human tissue factor: Interaction of factor VII and tissue factor in detergent micelles. Proc Nat Acad Sci USA 1986; 83: 299-302
26 Waxman E, Ross JBA, Laue T, Guha A, Thiruvikraman V, Lin TC, Konigsberg WH, Nemerson Y. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor Vila and enzymatic activity of the complex. Biochemistry 1992; 31: 3998-4003
27 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phos-phatidylserine. Biochemistry 1986; 25: 4007-4020
28 Ruf W, Miles D, Rehemtulla A, Edgington TS. Tissue factor residues 157167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267: 22206-22210
29 Stormorken H. Species differences of clotting factors in ox, dog, horse and man. Thromboplastin and Proconvertin. Acta Physiol. Scand 157 (41) 301-324
30 Ploplis VA, Edgington TS, Fair DS. Initiation of the extrinsic of coagulation: association of factor Vila with a cell line expressing tissue factor. J Biol Chem 1987; 262: 9503-9508
31 Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934-6938
32 De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor. Crystal structure of the complex. Science 1992; 255: 306-312
33 Ruf W, Schullek JR, Stone MJ, Edgington TS. Mutational mapping of functional residues in tissue factor: Identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. Biochemistry 1994; 33: 1565-1572
34 Baron M, Main AL, Driscoll PC, Mardon HJ, Boys J, Campbell ID. (1992) H-NMR assignment and secondary structure of the cell adhesion type III module of fibronectin. Biochemistry 1992; 31: 2068-2073
35 Leahy DJ, Hendrickson WA, Aukhil I, Erickson HP. Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. Science 1992; 258: 987-991
36 Huber AH, Wang YE, Bieber AJ, Bjorkman PJ. Crystal structure of tandem type III fibronectin domains from Drosophila neuroglian at 2.0 A. Neuron 1994; 12: 717-731
37 Waxman E, Laws WR, Laue TM, Nemerson Y, Ross JBA. Human factor Vila and its complex with soluble tissue factor: evaluation of asymmetry and conformational dynamics by ultracentrifugation and fluorescence anisotropy decay methods. Biochemistry 1993; 32: 3005-3012
38 Schullek JR, Ruf W, Edgington TS. Key ligand interface residues in tissue factor contribute independently to factor Vila binding. J Biol Chem 1994; 269: 19399-19403
39 Gibbs C, McCurdy S, Leung L, Paborsky L. Identification of the factor Vila binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994; 33: 14003-14010
40 Ruf W, Kelly CR, Schullek JR, Martin DMA, Polikarpov I, Boys CWG, Tuddenham EGD, Edgington TS. Energetic contributions and topographical organization of ligand binding residues of tissue factor. Biochemistry 1995; 34: 6310-6316
41 Martin DMA, Boys CWG, Ruf W. Tissue factor: molecular recognition and cofactor function. FASEB Journal 1995; 9: 852-859